Karyopharm Therapeutics (KPTI) Competitors $6.14 -0.37 (-5.62%) As of 02:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KPTI vs. CGEN, PLX, MCRB, OKYO, SPRO, TARA, IOBT, GNLX, AVTX, and IMRXShould you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include Compugen (CGEN), Protalix BioTherapeutics (PLX), Seres Therapeutics (MCRB), OKYO Pharma (OKYO), Spero Therapeutics (SPRO), Protara Therapeutics (TARA), IO Biotech (IOBT), Genelux (GNLX), Avalo Therapeutics (AVTX), and Immuneering (IMRX). These companies are all part of the "pharmaceutical products" industry. Karyopharm Therapeutics vs. Its Competitors Compugen Protalix BioTherapeutics Seres Therapeutics OKYO Pharma Spero Therapeutics Protara Therapeutics IO Biotech Genelux Avalo Therapeutics Immuneering Karyopharm Therapeutics (NASDAQ:KPTI) and Compugen (NASDAQ:CGEN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership. Do insiders & institutionals hold more shares of KPTI or CGEN? 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 12.2% of Compugen shares are owned by institutional investors. 3.0% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 9.5% of Compugen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media prefer KPTI or CGEN? In the previous week, Karyopharm Therapeutics had 5 more articles in the media than Compugen. MarketBeat recorded 5 mentions for Karyopharm Therapeutics and 0 mentions for Compugen. Compugen's average media sentiment score of 1.00 beat Karyopharm Therapeutics' score of 0.56 indicating that Compugen is being referred to more favorably in the news media. Company Overall Sentiment Karyopharm Therapeutics Positive Compugen Positive Do analysts recommend KPTI or CGEN? Karyopharm Therapeutics currently has a consensus price target of $34.00, suggesting a potential upside of 455.01%. Compugen has a consensus price target of $4.00, suggesting a potential upside of 179.72%. Given Karyopharm Therapeutics' higher probable upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Compugen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Karyopharm Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Compugen 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, KPTI or CGEN? Karyopharm Therapeutics has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500. Comparatively, Compugen has a beta of 2.61, meaning that its share price is 161% more volatile than the S&P 500. Which has preferable earnings and valuation, KPTI or CGEN? Compugen has lower revenue, but higher earnings than Karyopharm Therapeutics. Compugen is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKaryopharm Therapeutics$145.24M0.37-$76.42M-$14.59-0.42Compugen$27.86M4.58-$14.23M-$0.22-6.50 Is KPTI or CGEN more profitable? Compugen has a net margin of -87.45% compared to Karyopharm Therapeutics' net margin of -90.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Compugen's return on equity.Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics-90.02% N/A -84.28% Compugen -87.45%-34.77%-16.82% SummaryCompugen beats Karyopharm Therapeutics on 9 of the 16 factors compared between the two stocks. Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPTI vs. The Competition Export to ExcelMetricKaryopharm TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.29M$2.49B$5.76B$9.55BDividend YieldN/A1.66%4.53%4.07%P/E Ratio-0.4222.4930.4325.11Price / Sales0.37548.74392.2187.48Price / CashN/A173.7937.0358.50Price / Book-0.225.259.016.20Net Income-$76.42M$31.83M$3.26B$265.38M7 Day Performance31.74%0.56%1.00%-1.25%1 Month Performance52.39%3.47%4.19%-0.81%1 Year Performance-49.54%9.45%28.39%18.83% Karyopharm Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPTIKaryopharm Therapeutics3.8928 of 5 stars$6.13-5.8%$34.00+455.0%-45.1%$53.29M$145.24M-0.42380CGENCompugen1.887 of 5 stars$1.50flat$4.00+166.7%-23.4%$133.86M$27.86M-6.8270Positive NewsPLXProtalix BioTherapeutics3.0584 of 5 stars$1.61+4.5%$15.00+831.7%+65.1%$128.17M$59.76M-12.38200News CoverageAnalyst RevisionMCRBSeres Therapeutics3.2348 of 5 stars$14.53+2.3%$73.67+407.0%+4.2%$124.40M$126.32M-3.16330OKYOOKYO Pharma2.4762 of 5 stars$3.12-4.6%$7.00+124.4%+138.8%$122.99MN/A0.007SPROSpero Therapeutics3.7799 of 5 stars$2.20+0.5%$5.00+127.3%+46.4%$122.44M$47.98M-1.72150TARAProtara Therapeutics1.8411 of 5 stars$3.10-1.0%$20.50+561.3%+37.7%$120.76MN/A-1.8030News CoverageAnalyst RevisionIOBTIO Biotech3.0273 of 5 stars$1.05-42.0%$9.33+788.9%+19.0%$119.24MN/A-0.7030Earnings ReportHigh Trading VolumeGNLXGenelux1.4777 of 5 stars$3.28+4.1%$17.75+441.2%+64.7%$118.99M$10K-3.8110News CoverageAVTXAvalo Therapeutics3.3239 of 5 stars$9.01+0.9%$30.00+233.0%+3.5%$117.45M$440K0.0040IMRXImmuneering3.5591 of 5 stars$3.21-1.2%$13.25+312.8%+220.6%$116.95M$320K-1.6460News CoverageGap Up Related Companies and Tools Related Companies Compugen Competitors Protalix BioTherapeutics Competitors Seres Therapeutics Competitors OKYO Pharma Competitors Spero Therapeutics Competitors Protara Therapeutics Competitors IO Biotech Competitors Genelux Competitors Avalo Therapeutics Competitors Immuneering Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPTI) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access